Search
Search Results
##search.searchResults.foundPlural##
-
ASSOCIATION OF BASELINE PLATELET COUNT WITH COMPLETE REMISSION, SEVERE BLEEDING, AND 24-MONTH OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY
42PDF: 18Suppl. Files: 3Html: 6Html Suppl. Files: 5 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2272PDF: 1826HTML: 834 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2904PDF: 1048HTML: 5636 -
-
REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE
12914PDF: 1728HTML: 4350Cover letter: 222Figure 1: 230 -
IMPACT OF QUALITATIVE AND QUANTITATIVE IMMUNOPARESIS ON EARLY INFECTION RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Immunoparesis and early infection risk in myeloma
178PDF: 592HTML: 63 -
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
1436PDF: 480HTML: 128 -
-
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2130PDF: 881HTML: 359 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
2129PDF: 595HTML: 362 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
182PDF: 175HTML: 45 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
3154PDF: 1304HTML: 11859 -
CHILDREN IN CORONAVIRUSES’ WONDERLAND: WHAT CLINICIANS NEED TO KNOW Corona virus and Children
1522PDF: 1003HTML: 510 -
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3344PDF: 1509HTML: 5963Fig1-Ag-Pil: 259Ag-Pil Fig.2: 258 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4539PDF: 3724HTML: 371 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1462HTML: 635PDF: 872 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1776PDF: 1317HTML: 603 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2545HTML: 301PDF: 936 -
IDENTİFİCATİON OF LEİSHMANİA TROPİCA FROM PEDİATRİC VİSCERAL LEİSHMANİASİS İN SOUTHERN MEDITERRANEAN REGION OF TURKEY. Molecular characterization of pediatric visceral leishmaniasis
1077PDF: 736HTML: 275 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1795PDF: 1232HTML: 329 -
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
4144PDF: 1194HTML: 2106Fig.1: 227Fig. 2: 122Table 1: 223Table2: 242Table 3: 222 -
-
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2548PDF: 1727HTML: 498 -
FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients
1088PDF: 647Html: 171 -
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India
3479PDF: 819HTML: 3021Figure 1a and 1b: 170Figure 2: 178Figure 3: 197Figure 4: 176Figure 5: 179Tables 1-5: 166 -
FROM LEGACY TO INNOVATION: PIDOTIMOD’S EXPANDING THERAPEUTIC HORIZON Pidotimod: Revisiting a Classic Immunomodulator
2997PDF: 1051HTML: 1134







